Log In
Print
BCIQ
Print
Print this Print this
 

I-131-MIP-1466

  Manage Alerts
Collapse Summary General Information
Company Progenics Pharmaceuticals Inc.
DescriptionSmall molecule radiopharmaceutical targeting prostate-specific antigen (KLK3; PSA)
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationProstate cancer
Indication DetailsTreat prostate cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today